NEWS
BioCryst Announces Approval of Orladeyo (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Announces Approval of Orladeyo (berotralstat) by the Brazilian Health Regulatory Agency Biocryst Pharmaceuticals Inc announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily Orladeyo (berotralstat) for the prophylaxis [...]
Pharvaris reports Q4 and full year 2023 financial results and provides business update
Pharvaris reports fourth quarter and full year 2023 financial results and provides business update Pharvaris reported financial results for the fourth quarter and year ended 31 December 2023, and provided a business update. Berndt [...]
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference Pharvaris announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be [...]
KalVista Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
21 March 2024 KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals announced that it presented multiple analyses of the relationship [...]
Pharvaris announces Phase 3 clinical study design for recently initiated RAPIDe-3 study, and presents QoL improvement and caregiver behavior data
Pharvaris announces Phase 3 clinical study design for recently initiated RAPIDe-3 study, and presents quality-of-life improvement and caregiver behavior data at two recent HAE congresses Pharvaris presented at two recent congresses: the 3rd National [...]
Pharming reports fourth quarter and full year 2023 financial results
Pharming Group reports fourth quarter and full year 2023 financial results Pharming Group presents its preliminary (unaudited) financial report for the three months and full year ended 31 December 2023. Sijmen de Vries, Chief [...]
KalVista awarded UK Promising Innovative Medicine designation for sebetralstat
KalVista Pharmaceuticals awarded UK Promising Innovative Medicine (PIM) designation for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Promising Innovative Medicine (PIM) designation for sebetralstat, [...]
KalVista reports third fiscal quarter results and provides operational update
KalVista Pharmaceuticals reports third fiscal quarter results and provides operational update KalVista Pharmaceuticals today provided an operational update and released financial results for the third fiscal quarter ended 31 January 2024. Ben Palleiko, Chief [...]
KalVista to present HAE attack journey data at 2024 HAEi Regional Conference Americas
KalVista Pharmaceuticals to present HAE attack journey data at 2024 HAEi Regional Conference Americas KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama [...]
Astria reports Q4 and full year 2023 financial results and provides a corporate update
Astria Therapeutics reports fourth quarter and full year 2023 financial results and provides a corporate update Astra Therapeutics today announced today reported financial results for the fourth quarter and full year ended 31 December [...]
BioCryst reports Q4 and full year 2023 financial results and upcoming key milestones
BioCryst reports fourth quarter and full year 2023 financial results and upcoming key milestones Biocryst Pharmaceuticals Inc today reported financial results for the fourth quarter and full year ended 31 December 2023, and provided [...]
KalVista presents additional phase-3 KONFIDENT data at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals presents additional phase-3 KONFIDENT data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented additional data on its phase 3 KONFIDENT trial [...]
KalVista presents data on unmet needs in HAE from a Patient Perspective at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals presents data on unmet needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced that it presented real-world data [...]
BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment
BioCryst presents new real-world data showing rapid, substantial and sustained HAE attack rate reductions after beginning Orladeyo (berotralstat) treatment Biocryst Pharmaceuticals Inc today announced new analyses of real-world use of oral, once-daily Orladeyo (berotralstat) [...]
Intellia announces Q4 and full-year 2023 financial results and highlights company progress
Intellia Therapeutics announces fourth quarter and full-year 2023 financial results and highlights recent company progress Intellia Therapeutics today reported operational highlights and financial results for the fourth quarter and year ended December 31, 2023. [...]
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting Pharvaris today announced the upcoming presentation of two posters at [...]
Astria to present at upcoming AAAAI Annual Meeting
Astria Therapeutics to present at upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Astra Therapeutics today announced that it will present final STAR-0215 Phase 1a healthy subject data at the upcoming [...]
BioCryst launches Orladeyo (berotralstat) in Italy
BioCryst launches Orladeyo (berotralstat) in Italy BioCryst Pharmaceuticals Inc today announced that the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), has finalized reimbursement and recommended Orladeyo (berotralstat) for the routine prevention of recurrent [...]
KalVista awarded UK innovation passport for sebetralstat
KalVista Pharmaceuticals awarded UK innovation passport for sebetralstat KalVista Pharmaceuticals today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein [...]
KalVista to present phase-3 sebetralstat data at the 2024 AAAAI Annual Meeting
KalVista Pharmaceuticals to present phase-3 sebetralstat data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting KalVista Pharmaceuticals today announced the acceptance of multiple abstracts at the 2024 American Academy of [...]
KalVista reports phase-3 KONFIDENT trial meets all endpoints for sebetralstat as first oral on-demand therapy for HAE
KalVista Pharmaceuticals reports phase-3 KONFIDENT trial meets all endpoints for sebetralstat as first oral on-demand therapy for hereditary angioedema KalVista Pharmaceuticals today announced positive results from the phase 3 KONFIDENT clinical trial demonstrating statistically [...]
CSL reports net profit after tax for six months ending 31 Dec 2023
CSL reports net profit after tax for six months ending 31 December 2023 CSL Limited announced a reported net profit after tax of $1.90 billion1 for the 6 months that ended 31 December 2023, [...]
BioCryst to present new Orladeyo (berotralstat) real-world data at 2024 AAAAI annual meeting
BioCryst to present new Orladeyo (berotralstat) real-world data at 2024 American Academy of Allergy, Asthma & Immunology annual meeting BioCryst Pharmaceuticals Inc today announced that the company will present five abstracts featuring new analyses [...]
Intellia announces publication of positive interim phase 1 data for NTLA-2002 in HAE patients
Intellia Therapeutics announces publication in the New England Journal of Medicine of positive interim phase 1 data for NTLA-2002 in patients with hereditary angioedema Intellia Therapeutics announced that interim results from the Phase 1 [...]
News from Venezuela
From Wilfredo Bocaranda, President, HAE Venezuela HAE Venezuela held meetings with the Authorities of the Military Hospital with Doctors Guillermo Boggiano, Rommy Boggiano, and their medical team to analyze the case of patients in [...]
Stay Tuned
Be the first to know what’s going on in the world of HAE
Upcoming events
Saudi Arabia
May 11, 2024
HAE Patient Workshop; HAE Saudi Arabia
May 16, 2024
hae day :-) 2024
Denmark
May 17, 2024
En tur i Regnbuen med HAE Scandinavia
Denmark
May 29, 2024
En tur i Laboratoriet med HAE Scandinavia
HAE related topics that might interest you
Global Perspectives
Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community
HAEi Advocacy Academy
Courses, advocacy training, and tools to support people living with HAE and becoming an HAE advocate
HAEi Connect Member database
Free, secure online membership database and communications platform for HAEi’s member organizations
HAE Companion app
Access to HAEi’s emergency card in many languages and ACARE Centers, HAE knowledgeable hospitals and physicians
Stay tuned – sign up for our newsletter
BE THE FIRST TO KNOW ABOUT HAE NEWS, TREATMENTS, EVENTS AND RELATED TOPICS
